Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-28. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
== Awards and recognition == Jimmy John's was named number one on the Entrepreneur 2016 Franchise 500. In 2014, YouGov BrandIndex ranked restaurant chains that have the highest millennial brand loyalty, and Jimmy John's topped the ranking with 83% of the vote based on restaurants they would consider going to again. Jimmy John's was named the #2 Most Popular Restaurant for Business Meals by expense reporting program Certify. In 2015, Entrepreneur.com named Jimmy John's one of the 10 Promising Franchises for Ambitious Entrepreneurs. In March 2017, Jimmy John's won Franchise Times' "Deal of the Year" for attracting Roark Capital Group as the company's new majority owner. FT's judges called the deal "one of the best private equity deals of all time in the restaurant business." In 2011 CNN Money listed Jimmy John's as one of ten "Great Franchise Bets". The company estimates that annual sales can be as high as $1.2 million while net profits can average at about $280,000. Real estate start-up costs are estimated to be between $305,000 and $485,500.
== Comorbidity == Fibromyalgia as a stand-alone diagnosis is uncommon, as most fibromyalgia patients often have other chronic overlapping pain problems, mental disorders or other medical conditions. Comorbidities may be associated with more intense pain and other symptoms. Fibromyalgia is associated with mental health issues, including anxiety, post-traumatic stress disorder (PTSD), bipolar disorder, alexithymia, and depressive disorders. Approximately one-third of patients presenting with an FM diagnosis also meet the criteria for PTSD, and are five times more likely to have major depressive disorder than the general population. The pain and limited energy of fibromyalgia often leads to less activity, leading to social isolation and increased stress levels—both of which tend to cause anxiety and depression. Separation of depression symptoms from those of fibromyalgia is difficult. Chronic pain conditions are often comorbid with fibromyalgia, including neuropathic pain, chronic tension headaches, myofascial pain syndrome, and temporomandibular joint dysfunction. Neurological disorders that have been linked to pain or fibromyalgia include multiple sclerosis, post-polio syndrome, and Parkinson's disease. Fibromyalgia may share pathogenetic overlap with other syndromes, including myalgic encephalomyelitis/chronic fatigue syndrome and irritable bowel syndrome (IBS). Fibromyalgia has been reported to occur as a comorbidity in 20–30% of individuals with rheumatic diseases, including rheumatoid arthritis (RA).
A cocurrent heat exchanger is an example of a cocurrent flow exchange mechanism. Two tubes have a liquid flowing in the same direction. One starts off hot at 60 °C (140 °F), the second cold at 20 °C (68 °F). A thermoconductive membrane or an open section allows heat transfer between the two flows. The hot fluid heats the cold one, and the cold fluid cools down the warm one. The result is thermal equilibrium: Both fluids end up at around the same temperature: 40 °C (104 °F), almost exactly between the two original temperatures (20 °C (68 °F) and 60 °C (140 °F)). At the input end, there is a large temperature difference of 40 °C (104 °F) and much heat transfer; at the output end, there is a very small temperature difference (both are at the same temperature of 40 °C (104 °F) or close to it), and very little heat transfer if any at all. If the equilibrium—where both tubes are at the same temperature—is reached before the exit of the liquid from the tubes, no further heat transfer will be achieved along the remaining length of the tubes. A similar example is the cocurrent concentration exchange. The system consists of two tubes, one with brine (concentrated saltwater), the other with freshwater (which has a low concentration of salt in it), and a semi permeable membrane which allows only water to pass between the two, in an osmotic process. Many of the water molecules pass from the freshwater flow in order to dilute the brine, while the concentration of salt in the freshwater constantly grows (since the salt is not leaving this flow, while water is).
Sources: en.wikipedia.org
== Legal status == DNP is banned for human consumption in many countries. Because it has some legitimate uses, in many jurisdictions, DNP is legal to sell, but not for human consumption. DNP has been banned by the World Anti-Doping Association since 2015. Petróczi et al. recommend against campaigns informing people of the risks of DNP because it could increase use of the drug. However, Sousa et al. argue that publicity campaigns in the United Kingdom in the early and mid-2010s reduced DNP usage. In 2015, Interpol and the World Anti-Doping Agency released an orange notice warning of the dangers of DNP. In 1941, the Eastman Kodak Company, a bulk distributor of DNP, was investigated after some of its product was found in illegal diet pills. Nicholas Bachynsky, a Texas physician, provided the drug to patients under the name "Mitcal". He was convicted of violating drug laws in 1986, but continued to work with DNP and was additionally convicted of fraud in 2008. In 2018, a seller in the United Kingdom was convicted of manslaughter for selling DNP for human consumption. The conviction was sent to retrial in 2020 by the English Court of Appeal, where the seller was, once again, convicted of gross negligence manslaughter. The UK government reclassified DNP as a regulated poison with effect from October 2023.
The Unitized Group Ration – Heat & Serve (UGR-H&S) is the successor to the T-ration, and consists of precooked, shelf-stable tray pack entrées. The UGR-H&S is hermetically sealed and can be prepared using a tray ration heater or by immersing it in boiling water, ready to serve in 30 to 45 minutes. The UGR-H&S has 5 breakfast menus and 10 lunch/dinner menus. Each meal provides an average of 1,450 kcal. Each UGR-H&S module contains 50 meals, with each pallet holding 400 meals. UGR-H&S modules have a minimum shelf life of 18 months at 80 °F (26.6 °C).
Experts anticipate that future microfluidic-based innovations for directed evolution campaigns will be driven in the commercial space, resulting in more simple and less expensive methods and tools that can be applied to biotechnologically-relevant enzymes.
=== Chemical fingerprinting and breath analysis === The exhaled human breath contains a few thousand volatile organic compounds and is used in breath biopsy and is used in breath biopsy as a biomarker to test for diseases, such as lung cancer. One study has shown that "volatile organic compounds ... are mainly blood borne and therefore enable monitoring of different processes in the body." And it appears that VOC compounds in the body "may be either produced by metabolic processes or inhaled/absorbed from exogenous sources" such as environmental tobacco smoke. Chemical fingerprinting and breath analysis of volatile organic compounds has also been demonstrated with chemical sensor arrays, which utilize pattern recognition for detection of component volatile organics in complex mixtures such as breath gas.
Sources: en.wikipedia.org
===== Resident compensation ===== Starting from the first year of postgraduate training residents trained in the US receive compensation. According to the Medscape Residents Salary & Debt Report, in 2021 the average resident annual salary was US$64,000. In 2021, 43% of trainees polled were satisfied with their compensation according to Medcape's report.
Based on solution structures and sequence alignments, bacteriocins appear to take on similar 3D structures despite little sequence homology, contributing to stability and resistance to degradation. Conopeptides and other toxoglossan peptides are the components of the venom of predatory marine snails, such as the cone snails or Conus. Venom peptides from cone snails are generally smaller than those found in other animal venoms (10-30 amino acids vs. 30-90 amino acids) and have more disulfide crosslinks. A single species may have 50-200 conopeptides encoded in its genome, recognizable by a well-conserved signal sequence. Cyclotides are RiPPs with a head-to-tail cyclization and three conserved disulfide bonds that form a knotted structure called a cyclic cysteine knot motif. No other posttranslational modifications have been observed on the characterized cyclotides, which are between 28 - 37 amino acids in size. Cyclotides are plant natural products and the different cyclotides appear to be species-specific. While many activities have been reported for cyclotides, it has been hypothesized that all are united by a common mechanism of binding to and disrupting the cell membrane. Glycocins are RiPPs that are glycosylated antimicrobial peptides. Only two members have been fully characterized, making this a small RiPP class. Sublancin 168 and glycocin F are both Cys-glycosylated and, in addition, have disulfide bonds between non-glycosylated Cys residues.
People with a history of a substance use disorder or substance dependence. Research suggests that diazepam may increase motivation for alcohol consumption and cravings in some individuals with a history of problematic drinking. People with severe personality disorders, such as borderline personality disorder. Patients from the aforementioned groups are monitored closely during therapy for signs of abuse and the development of dependence. Therapy is recommended to be discontinued if any of these signs are noted. If dependence has developed, therapy is still discontinued gradually to avoid severe withdrawal symptoms. Long-term therapy in such instances is not recommended. People suspected of being dependent on benzodiazepine drugs are gradually tapered off the drug. Withdrawals can be life-threatening, particularly when excessive doses have been taken for extended periods. Therefore, equal prudence is used whether dependence has occurred in therapeutic or recreational contexts. Diazepam is seen as a good choice for tapering for those using high doses of other benzodiazepines since it has a long half-life, thus withdrawal symptoms are tolerable. The process is slow (usually from 14 to 28 weeks) but is considered safe when done appropriately.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
Filtering removes particulate matter that can block columns or scatter light. A 0.22 micrometre membrane is typical, and the filter material should be checked for peptide adsorption.